• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Guidelines for Reporting Adverse Events

Guidelines for Reporting Adverse Events

Friday, 18 December 2020 / Published in Medical Device, News, NMPA Registration in China

Guidelines for Reporting Adverse Events

On November 27, 2020, the National Medical Products Administration (NMPA) issued (No.78 – 2020) the guideline for the standard procedure that NMPA Legal Agents shall follow when submitting risk evaluation reports after an adverse event.

In general, the medical device registrants or filing persons are responsible to verify the investigation results of the adverse event, analyse the data collected from post-market surveillance and other risk reports, arrange product inspections, prepare the analysis, evaluation, and control of risks.

According to the guidelines, the medical device registrants or filing persons are advised to investigate, analyse and evaluate the occurrence of the adverse event within a short turnaround time. The medical device registrant or filing person should be prepared to carry out a risk evaluation report if any unreasonable risks of the product are identified, which could be required by the respective MPA or self-initiated by the medical device registrant or filing person.

If the medical device registrants is requested by a government official to submit the risk evaluation report, it should always be submitted directly to the National Center for ADR (Adverse Drug Reaction) Monitoring in China. Otherwise, if the risk evaluation work is self-initiated by the medical device registrant or filing person, the report should only be submitted to the local MPA, and the local MPA should forward the report to the National Center for ADR Monitoring.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Adverse Events, Period Risk Evaluation Report

What you can read next

Latest Technical Review Guidelines Issued / Updated
Cosmetics enterprises quality and safety responsibilities
Cosmetics enterprises quality and safety responsibilities – Draft regulation issued
Administrative Measure on Cosmetics Registration and Filing

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.